Cysteine cathepsin proteases as pharmacological targets in cancer

Trends in Pharmacological Sciences

Volumn 29, Issue 1, 2008, Pages 22-28

  Palermo, Carmela ^a   Joyce, Johanna A ^a  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AFG 495; BALICATIB; CATHEPSIN; CATHEPSIN K; CATHEPSIN S; CRA 013783; CRA 028129; CYSTEINE CATHEPSIN PROTEASE; CYSTEINE PROTEINASE; CYSTEINE PROTEINASE INHIBITOR; MATRIX METALLOPROTEINASE INHIBITOR; MIV 701; MK 0822; N (3 PROPYLCARBAMOYLOXIRANE 2 CARBONYL)ISOLEUCYLPROLINE; N [N (3 CARBOXYOXIRANE 2 CARBONYL)LEUCYL]AGMATINE; OST 4077; RELACATIB; RWJ 445380; SB 553484; UNCLASSIFIED DRUG;

ANGIOGENESIS; ARTICLE; BONE DEFECT; BONE DISEASE; BONE METASTASIS; BREAST CANCER; CANCER GROWTH; CANCER INVASION; CARCINOGENESIS; CLINICAL TRIAL; DRUG ACTIVITY; DRUG EFFICACY; ENZYME ACTIVITY; ENZYME INHIBITION; HUMAN; METASTASIS; NONHUMAN; OSTEOARTHRITIS; OSTEOPOROSIS; PRIORITY JOURNAL; PROGNOSIS; PROTEIN DEGRADATION; PROTEIN EXPRESSION; PSORIASIS; RHEUMATOID ARTHRITIS; TREATMENT INDICATION; UPREGULATION;

ANIMALS; ANTINEOPLASTIC AGENTS; CATHEPSINS; CLINICAL TRIALS AS TOPIC; CYSTEINE PROTEINASE INHIBITORS; DISEASE MODELS, ANIMAL; DISEASE PROGRESSION; DRUG DELIVERY SYSTEMS; DRUG EVALUATION, PRECLINICAL; HUMANS; NEOPLASMS; UP-REGULATION;

EID: 37549070672     PISSN: 01656147     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.tips.2007.10.011     Document Type: Article

References (62)

1. Gocheva V., and Joyce J.A. Cysteine cathepsins and the cutting edge of cancer invasion. Cell Cycle 6 (2007) 60-64
2. Gupta G.P., and Massague J. Cancer metastasis: building a framework. Cell 127 (2006) 679-695
3. Berdowska I. Cysteine proteases as disease markers. Clin. Chim. Acta 342 (2004) 41-69
4. Duffy M.J., and Duggan C. The urokinase plasminogen activator system: a rich source of tumour markers for the individualised management of patients with cancer. Clin. Biochem. 37 (2004) 541-548
5. Overall C.M., and Kleifeld O. Tumour microenvironment - opinion: validating matrix metalloproteinases as drug targets and anti-targets for cancer therapy. Nat. Rev. Cancer 6 (2006) 227-239
6. Puente X.S., et al. Human and mouse proteases: a comparative genomic approach. Nat. Rev. Genet. 4 (2003) 544-558
7. Coussens L.M., et al. Matrix metalloproteinase inhibitors and cancer: trials and tribulations. Science 295 (2002) 2387-2392
8. Turk B. Targeting proteases: successes, failures and future prospects. Nat. Rev. Drug Discov. 5 (2006) 785-799
9. Mohamed M.M., and Sloane B.F. Cysteine cathepsins: multifunctional enzymes in cancer. Nat. Rev. Cancer 6 (2006) 764-775
10. Joyce J.A., et al. Cathepsin cysteine proteases are effectors of invasive growth and angiogenesis during multistage tumorigenesis. Cancer Cell 5 (2004) 443-453
11. Bell-McGuinn K.M., et al. Inhibition of cysteine cathepsin protease activity enhances chemotherapy regimens by decreasing tumor growth and invasiveness in a mouse model of multistage cancer. Cancer Res. 67 (2007) 7378-7385
12. Turk V., et al. Lysosomal cysteine proteases: facts and opportunities. EMBO J. 20 (2001) 4629-4633
13. Reinheckel T., et al. Towards specific functions of lysosomal cysteine peptidases: phenotypes of mice deficient for cathepsin B or cathepsin L. Biol. Chem. 382 (2001) 735-741
14. Saftig P., et al. Impaired osteoclastic bone resorption leads to osteopetrosis in cathepsin-K-deficient mice. Proc. Natl. Acad. Sci. U. S. A. 95 (1998) 13453-13458
15. Shi G.P., et al. Cathepsin S required for normal MHC class II peptide loading and germinal center development. Immunity 10 (1999) 197-206
16. Yasuda Y., et al. The role of cathepsins in osteoporosis and arthritis: rationale for the design of new therapeutics. Adv. Drug Deliv. Rev. 57 (2005) 973-993
17. Rao J.S. Molecular mechanisms of glioma invasiveness: the role of proteases. Nat. Rev. Cancer 3 (2003) 489-501
18. Grimm J., et al. Use of gene expression profiling to direct in vivo molecular imaging of lung cancer. Proc. Natl. Acad. Sci. U. S. A. 102 (2005) 14404-14409
19. Jedeszko C., and Sloane B.F. Cysteine cathepsins in human cancer. Biol. Chem. 385 (2004) 1017-1027
20. Joyce J.A., and Hanahan D. Multiple roles for cysteine cathepsins in cancer. Cell Cycle 3 (2004) 1516-1519
21. Koblinski J.E., et al. Unraveling the role of proteases in cancer. Clin. Chim. Acta 291 (2000) 113-135
22. Kos J., et al. Cysteine proteinases and their inhibitors in extracellular fluids: markers for diagnosis and prognosis in cancer. Int. J. Biol. Markers 15 (2000) 84-89
23. + exchanger in metastasis. Nat. Rev. Cancer 5 (2005) 786-795
24. Otto H.H., and Schirmeister T. Cysteine proteases and their inhibitors. Chem. Rev. 97 (1997) 133-172
25. Vasiljeva O., et al. Emerging roles of cysteine cathepsins in disease and their potential as drug targets. Curr. Pharm. Des. 13 (2007) 385-401
26. Hanada K., et al. Isolation and characterization of E-64, a new thiol proteinase inhibitor. Agric. Biol. Chem. 42 (1978) 523-528
27. Redwood S.M., et al. Abrogation of the invasion of human bladder tumor cells by using protease inhibitor(s). Cancer 69 (1992) 1212-1219
28. Navab R., et al. Inhibition of carcinoma cell invasion and liver metastases formation by the cysteine proteinase inhibitor E-64. Clin. Exp. Metastasis 15 (1997) 121-129
29. Moldoveanu T., et al. Crystal structures of calpain-E64 and -leupeptin inhibitor complexes reveal mobile loops gating the active site. J. Mol. Biol. 343 (2004) 1313-1326
30. Meara J.P., and Rich D.H. Mechanistic studies on the inactivation of papain by epoxysuccinyl inhibitors. J. Med. Chem. 39 (1996) 3357-3366
31. Towatari T., et al. Novel epoxysuccinyl peptides. A selective inhibitor of cathepsin B, in vivo. FEBS Lett. 280 (1991) 311-315
32. Katunuma N., et al. Structure based development of novel specific inhibitors for cathepsin L and cathepsin S in vitro and in vivo. FEBS Lett. 458 (1999) 6-10
33. + T cell differentiation from Th2 to Th1 by treatment with cathepsin B inhibitor in experimental leishmaniasis. J. Immunol. 161 (1998) 2120-2127
34. Saegusa K., et al. Cathepsin S inhibitor prevents autoantigen presentation and autoimmunity. J. Clin. Invest. 110 (2002) 361-369
35. Onishi K., et al. Cathepsin L is crucial for a Th1-type immune response during Leishmania major infection. Microbes Infect. 6 (2004) 468-474
36. Sadaghiani A.M., et al. Design, synthesis, and evaluation of in vivo potency and selectivity of epoxysuccinyl-based inhibitors of papain-family cysteine proteases. Chem. Biol. 14 (2007) 499-511
37. Abdulla M.H., et al. Schistosomiasis mansoni: novel chemotherapy using a cysteine protease inhibitor. PLoS Med. 4 (2007) e14
38. Renslo A.R., and McKerrow J.H. Drug discovery and development for neglected parasitic diseases. Nat. Chem. Biol. 2 (2006) 701-710
39. Riese R.J., et al. Cathepsin S activity regulates antigen presentation and immunity. J. Clin. Invest. 101 (1998) 2351-2363
40. Clark A.K., et al. Inhibition of spinal microglial cathepsin S for the reversal of neuropathic pain. Proc. Natl. Acad. Sci. U. S. A. 104 (2007) 10655-10660
41. Grabowskal U., et al. Recent developments in cathepsin K inhibitor design. Curr. Opin. Drug Discov. Dev. 8 (2005) 619-630
42. Grosios, K. et al. (2005) Efficacy of the bisphosphonate Zometa(R) and the selective cathepsin K inhibitor AFG495 administered alone or in combination in a murine xenograft model of breast cancer cell induced osteolysis [abstract]. In Proceedings of the 96th American Association for Cancer Research Meeting; Apr 16-20; Anaheim, CA: AACR (2005) 46, p 683
43. Xiang A., et al. Changes in micro-CT 3D bone parameters reflect effects of a potent cathepsin K inhibitor (SB-553484) on bone resorption and cortical bone formation in ovariectomized mice. Bone 40 (2007) 1231-1237
44. Le Gall C., Bellahcene A., et al. A cathepsin K inhibitor reduces breast cancer induced osteolysis and skeletal tumor burden. Cancer Res. 67 (2007) 9894-9902
45. Grubb A., et al. Synthesis of cysteine proteinase inhibitors structurally based on the proteinase interacting N-terminal region of human cystatin C. Biol. Chem. Hoppe Seyler 371 Suppl. (1990) 137-144
46. Wieczerzak E., et al. Azapeptides structurally based upon inhibitory sites of cystatins as potent and selective inhibitors of cysteine proteases. J. Med. Chem. 45 (2002) 4202-4211
47. Bjorck L., et al. Bacterial growth blocked by a synthetic peptide based on the structure of a human proteinase inhibitor. Nature 337 (1989) 385-386
48. Kopitz C., et al. Reduction of experimental human fibrosarcoma lung metastasis in mice by adenovirus-mediated cystatin C overexpression in the host. Cancer Res. 65 (2005) 8608-8612
49. Konduri S.D., et al. Modulation of cystatin C expression impairs the invasive and tumorigenic potential of human glioblastoma cells. Oncogene 21 (2002) 8705-8712
50. Li W., et al. Overexpression of stefin A in human esophageal squamous cell carcinoma cells inhibits tumor cell growth, angiogenesis, invasion, and metastasis. Clin. Cancer Res. 11 (2005) 8753-8762
51. Falgueyret J.P., et al. Lysosomotropism of basic cathepsin K inhibitors contributes to increased cellular potencies against off-target cathepsins and reduced functional selectivity. J. Med. Chem. 48 (2005) 7535-7543
52. Bergers G., et al. Matrix metalloproteinase-9 triggers the angiogenic switch during carcinogenesis. Nat. Cell Biol. 2 (2000) 737-744
53. Van Noorden C.J., et al. Heterogeneous suppression of experimentally induced colon cancer metastasis in rat liver lobes by inhibition of extracellular cathepsin B. Clin. Exp. Metastasis 16 (1998) 159-167
54. Van Noorden C.J., et al. In vivo inhibition of cysteine proteinases delays the onset of growth of human pancreatic cancer explants. Br. J. Cancer 82 (2000) 931-936
55. Gocheva V., et al. Distinct roles for cysteine cathepsin genes in multistage tumorigenesis. Genes Dev. 20 (2006) 543-556
56. Wang B., et al. Cathepsin S controls angiogenesis and tumor growth via matrix-derived angiogenic factors. J. Biol. Chem. 281 (2006) 6020-6029
57. Vasiljeva O., et al. Tumor cell-derived and macrophage-derived cathepsin B promotes progression and lung metastasis of mammary cancer. Cancer Res. 66 (2006) 5242-5250
58. Cremers S., and Garnero P. Biochemical markers of bone turnover in the clinical development of drugs for osteoporosis and metastatic bone disease: potential uses and pitfalls. Drugs 66 (2006) 2031-2058
59. Blum G., et al. Noninvasive optical imaging of cysteine protease activity using fluorescently quenched activity-based probes. Nat. Chem. Biol. 3 (2007) 668-677
60. Joyce J.A. Therapeutic targeting of the tumor microenvironment. Cancer Cell 7 (2005) 513-520
61. Lee K.K. Discontinued drugs in 2005: pulmonary-allergy, dermatological, gastrointestinal and arthritis drugs. Expert Opin. Investig. Drugs 15 (2006) 1497-1505
62. Kim M.K., et al. An orally active cathepsin K inhibitor, furan-2-carboxylic acid, 1-{1-[4-fluoro-2-(2-oxo-pyrrolidin-1-yl)-phenyl]-3-oxo-piperidin-4-ylcarbamoyl}-cyclohexyl)-amide (OST-4077), inhibits osteoclast activity in vitro and bone loss in ovariectomized rats. J. Pharmacol. Exp. Ther. 318 (2006) 555-562